Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602915" target="_blank" >RIV/61989592:15110/20:73602915 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/20:00116027 RIV/00216208:11110/20:10410153 RIV/00216208:11130/20:10410153 RIV/00216208:11140/20:10410153 and 5 more

Result on the web

<a href="https://link.springer.com/article/10.1007/s11523-020-00705-1" target="_blank" >https://link.springer.com/article/10.1007/s11523-020-00705-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11523-020-00705-1" target="_blank" >10.1007/s11523-020-00705-1</a>

Result language

angličtina

Original language name

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice

Original language description

Background Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in sequence with first- and second-line chemotherapy, especially in patients with RAS-mutated tumours. Objective The aim of the present study was to investigate the outcomes of patients with mCRC treated with the bevacizumab-aflibercept sequence in real-world clinical practice. Patients and Methods Data from a national clinical registry of targeted therapies for mCRC were analysed retrospectively. Overall, there were 366 patients with valid data who received first-line treatment with bevacizumab and chemotherapy followed by aflibercept with chemotherapy. The majority of the patients (n = 296, 80.8%) had RAS mutated tumours. Results Median cumulative progression-free survival (PFS) from the start of the bevacizumab-containing regimen to progression on aflibercept was 18.2 months (95% CI 16.8-19.5). Median PFS for bevacizumab and aflibercept was 10.6 months (95% CI 9.5-11.7) and 5.6 months (95% CI 5.1-6.1), respectively. Longer PFS on aflibercept was associated with metachronous metastatic disease and longer PFS on bevacizumab. Median overall survival (OS) from the start of first-line bevacizumab was 32.0 months (95% CI 26.6-37.5). The presence of metastatic disease at diagnosis was associated with worse OS. Conclusions Patients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Targeted Oncology

ISSN

1776-2596

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

2

Country of publishing house

FR - FRANCE

Number of pages

9

Pages from-to

193-201

UT code for WoS article

000513061300001

EID of the result in the Scopus database

2-s2.0-85079459209